Summary
The increased use of vancomycin in neonatal and paediatric patients has prompted numerous pharmacokinetic studies and the development of many empirical administration methods. The majority of dosage guidelines use the relationship between pharmacokinetic parameters and patient variables such as chronological age, body weight, and/or measures of renal function. Currently, those dosage guidelines which are based upon postconceptional age and body weight seem to provide the best options for empirical administration in neonates and infants. In addition, serum creatinine may prove to be a useful guide to the empirical administration of vancomycin in neonates older than 7 to 14 days.
Several investigators have reported the individualisation of dosage regimens based on pharmacokinetic-based administration methods. The most common techniques employed have been Sawchuk-Zaske method and Bayesian forecasting. However, only a limited number of studies have evaluated either empirical administration or individualised administration techniques in patient populations outside those of the original reports; this makes choosing between the methods difficult.
Pharmacokinetic data and administration recommendations have gradually become available in special paediatric patient populations. The majority of studies have focused on patients requiring cardiopulmonary bypass surgery or with burns, cancer or central nervous system infections. However, a limited amount of information is available regarding vancomycin disposition in children older than 1 year of age with and without end-stage renal failure.
The monitoring of serum vancomycin concentrations may be useful in selected neonatal and paediatric patient populations, especially where large interpatient variability occurs and administration guidelines are not clearly established. Similar to the literature on adults, the lack of conclusive evidence concerning the relationship between serum vancomycin concentrations and therapeutic responses leaves this topic open to debate.
Article PDF
Similar content being viewed by others
References
Spears RL, Koch R. The use of vancomycin in pediatrics. Antibiotics Ann 1959–1960: 798–803
Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119–26
Kaplan EL. Vancomycin in infants and children: a review of pharmacology and indications for therapy and prophylaxis. J Antimicrob Chemother 1984; 14 Suppl. D: 59–66
de Louvois J, Harvey D. Antibiotic therapy of the newborn. Clin Perinatol 1988; 15: 365–89
Hall SL. Coagulase-negative staphylococcal infections in neonates. Pediatr Infect Dis J 1991; 10: 57–67
Patrick CC. Coagulase-negative staphylococci: pathogens with increasing clinical significance. J Pediatr 1990; 116: 497–507
Battisti O, Mitchison R, Davies PA. Changing blood culture isolates in a referral neonatal intensive care unit. Arch Dis Child 1981; 56: 775–8
Hoogkamp-Korstanje KJ, Cats B, Senders RC, et al. Analysis of bacterial infections in a neonatal intensive care unit. J Hosp Infect 1982; 3: 275–84
Hack M, Horbar JD, Malloy MH, et al. Very low birth weight outcomes of the national institute of child health and human development neonatal network. Pediatrics 1991; 87: 587–97
Becerra JE, Fry YW, Rowley DL. Morbidity estimates of conditions originating in the perinatal period: United States, 1986 through 1987. Pediatrics 1991; 88: 553–9
Edwards MS, Baker CJ. Median sternotomy wound infections in children. Pediatr Infect Dis J 1983; 2: 105–9
Scherer LR, West KW, Weber TR, et al. Staphylococcus epidermidis sepsis in pediatric patients: clinical and therapeutic considerations. J Pediatr Surg 1984; 19: 358–61
Siegel JD, McCracken GH. Sepsis neonatorum. N Engl J Med 1981; 304: 642–7
Friedman LE, Brown AE, Miller DR, et al. Staphylococcus epidermidis septicemia in children with leukemia and lymphoma. Am J Dis Child 1984; 138: 715–9
Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods: Part IV: vancomycin. Clin Pharmacokine 1991; 20: 463–76
Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327–42
Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533–43
Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18: 544–6
Pryka RD. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother 1994; 28: 1397–9
Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995; 36: 279–82
Wandstrat TL, Phelps SJ. Vancomycin dosing in neonatal patients: the controversy continues. Neonatal Netw 1994; 13: 33–9
Morse GD, Nairn DK, Bertino JS, et al. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 1987; 9: 212–5
Anne L, Hu M, Chan K, et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989; 11: 585–91
Hu MW, Anne L, Forni T, et al. Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay. Ther Drug Monit 1990; 12: 562–9
White LO, Edwards R, Holt HA, et al. The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother 1988; 22: 739–45
Harris CM, Kopecka H, Harris TM. Vancomycin: structure and transformation to CDP-1. J Am Chem Soc 1983; 105: 6915–22
Paap CM, Sharpe GL. Overestimation of serum vancomycin concentrations using a fluorescence polarization immunoassay (TDx) in preterm neonates. Dev Pharmacol Ther 1993; 20: 174–9
Alpert G, Campos JM, Harris MC, et al. Vancomycin dosage in pediatrics reconsidered. Am J Dis Child 1984; 138: 20–2
Bailie GR, Ackerman BH, Fischer J, et al. Increased vancomycin dosage requirements in young burn patients. J Burn Care Rehabil 1984; 5: 376–8
Gross JR, Kaplan SL, Kramer WG, et al. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol 1985; 5: 17–22
Amaker RD, DiPiro JT. Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996; 40: 1139–42
Armstrong DK, Hidalgo HA, Eldadah M. Vancomycin and tobramycin clearance in an infant during continous hemofiltration. Ann Pharmacother 1993; 27: 224–7
Asbury WH, Darsey EH, Rose WB, et al. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993; 27: 490–6
Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J 1994; 13; 969–74
Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995; 14; 667–73
Gabriel MH, Kildoo CW, Gennrich JL, et al. Prospective evaluation of a vancomycin dosage guidelines for neonates. Clin Pharm 1991; 10: 129–32
Hatzopoulos FK, Stile-Calligaro IL, Rodvold KA, et al. Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. Pediatr Infect Dis J 1993; 12: 300–4
Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 1990; 9: 711–5
Jarrett RV, Marinkovich GA, Gayle EL, et al. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J 1991; 12: 156–7
Kildoo CW, Lin ML, Gabriel MH, et al. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1990; 14: 77–83
Koren G, James A. Vancomycin dosing in preterm infants: prospective verification of new dosing recommendation. J Pediatr 1987; 110: 797–8
Leonard MB, Koren G, Stevenson DK, et al. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 1989; 8: 282–6
Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35: 637–42
McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995; 17: 319–26
Moller JC, Nachtrodt G, Tegtmeyer FK, et al. Prophylactic low-dose vancomycin treatment in very-low-birth-weight infants. Dev Pharmacol Ther 1992; 19: 178–82
Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 1987; 22: 360–3
Rodvold KA, Gentry CA, Plank G, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239–46
Schaible DH, Rocci ML, Alpert GA, et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis J 1986; 5: 304–8
Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994; 56: 169–75
Naqvi SH, Keenan WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986; 140: 107–10
James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987; 31: 52–4
Riley HD, Ryan NJ. Treatment of severe staphylococcal infection in infancy and childhood with vancomycin. Antibiotic Ann 1959–1960: 908–16
Rodvold KA, Erdman SM, Pryka RD. Vancomycin. In: Schumacher GE, editor. Therapeutic drug monitoring. Norwalk: Appleton & Lange, 1996: 587–664
Schaad UB, Nelson JD, McCracken GH. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981; 3 Suppl.: 282–8
Levy M, Koren G, Dupuis L, et al. Vancomycin-induced red man syndrome. Pediatrics 1990; 86: 572–80
Odio C, Mohs E, Sklar FH, et al. Adverse reactions to vancomycin used as prophylaxis for CSF shunt procedures. Am J Dis Child 1984; 138: 17–9
Boussemart T, Cardona J, Bertheir M, et al. Cardiac arrest associated with vancomycin in a neonate [letter]. Arch Dis Child Fetal Neonatal 1995; 73: 123
Best CJ, Ewart M, Sumner E. Perioperative complications following the use of vancomycin in children: a report of two cases. Br J Anaesth 1989; 62: 576–7
Mayhew JF, Deutsch S. Cardiac arrest following administration of vancomycin. Can Anaesth Soc J 1985; 32: 65–6
Bergeron L, Boucher FD. Possible red-man syndrome associated with systemic absorption of oral vancomycin in a child with normal renal function. Ann Pharmacother 1994; 28: 581–4
Burkhart KK, Metcalf S, Shurnas E, et al. Exchange transfusion and multidose activated charcoal following vancomycin overdose. Clin Toxicol 1992; 30: 285–94
Linder N, Edwards R, McClead R, et al. Safety of vancomycin with or without gentamicin in neonates. Neonatal Netw 1993; 12: 27–30
Odio C, McCracken GH, Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984; 105: 491–3
Dean RP, Wagner DJ, Tolpin MD. Vancomycin/aminoglycoside nephrotoxicity [letter]. J Pediatr 1985; 106: 861–2
Tissing WJE, Umans-Eckenhausen MAW, van den Anker JN. Vancomycin intoxication in a preterm neonate [letter]. Eur J Pediatr 1993; 152: 700
Goren MP, Baker DK, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989; 8: 278–82
Bolinger AM, So MH, Winter ME. Aminoglycoside and vancomycin pharmacokinetic monitoring in pediatric patients [letter]. Am J Hosp Pharm 1989; 46: 1770–1
Banner W, Ray CG. Vancomycin in perspective. Am J Dis Child 1984; 138: 14–6
Gous AGS, Dance MD, Lipman J, et al. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth Intensive Care 1995; 23: 678–82
Thompson CM, Long SS, Gilligan PH, et al. Absorption of oral vancomycin: possible associated toxicity. Int J Pediatr Nephrol 1983; 4: 1–4
Luer MS, Hatton J. Vancomycin administration into the cerebrospinal fluid: a review. Ann Pharmacother 1993; 27: 912–21
Fan-Havard P, Nahata MC, Bartowski MH, et al. Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement. Chemotherapy 1990; 36: 103–8
McGee SM, Kaplan SL, Mason EO. Ventricular fluid concentrations of vancomycin in children after intravenous and intraventricular administration. Pediatr Infect Dis J 1990; 9: 138–9
Pau AK, Smego RA, Fisher MA. Intraventricular vancomycin: observations of tolerance and pharmacokinetics in two infants with ventricular shunt infections. Pediatr Infect Dis J 1986; 5: 93–6
Isaac DW, Pearson TA, Hurwitz CA, et al. Clinical and microbiologic aspects of Staphylococcus haemolyticus infections. Pediatr Infect Dis J 1993; 12: 1018–21
Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1988–92
Paris MM, Hickey SM, Uscher MI, et al. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38: 1320–4
Cabellos C, Martinez-Lacasa J, Martos A, et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 1995; 39: 2158–60
Bayston R, Hart CA, Barnicoat M. Intraventricular vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiatry 1987; 50: 1419–23
McLaurin RL, Frame PT. Treatment of infections with cerebrospinal fluid shunts. Rev Infect Dis 1987; 9: 595–603
Jacobs F, Delecluse F, Raftopoulos C, et al. Intraventricular vancomycin in CSF shunt infections. Neurosurgery 1987; 21: 112–3
Arroyo JC, Quindlen EA. Accumulation of vancomycin after intraventricular infusions. South Med J 1983; 76: 1554–5
Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993; 15: 263–6
Spivey JM, Gal P. Vancomycin pharmacokinetics in neonates [letter]. Am J Dis Child 1986; 140: 859
Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183–95
Murray WE. Vancomycin pharmacokinetics [letter]. Arch J Dis Child 1986; 140: 1096–7
Naqvi SH, Keenen W, Reichley R. Vancomycin pharmacokinetics in neonates [letter]. Am J Dis Child 1986; 140: 859
Baker D, Rotschafer JC, Sawchuk R, et al. Vancomycin pharmacokinetics [letter]. J Pediatr 1980; 97: 502–3
Gabriel MH, Gennrich JL. Vancomycin dosing for neonates [letter]. Pediatr Infect Dis J 1993; 12: 705–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rodvold, K.A., Everett, J.A., Pryka, R.D. et al. Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children. Clin-Pharmacokinet 33, 32–51 (1997). https://doi.org/10.2165/00003088-199733010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199733010-00004